WILMINGTON, Mass., June 25, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today announced today
its QS-B220 desktop explosives and drugs trace detector has won the
2015 GSN Airport/Seaport/Border Security Award for "Best Security
Checkpoint" (persons, baggage, parcels). The QS-B220 was also a
finalist in two other categories: "Best
Explosives/Narcotics/Contraband Detection" and "Best Cargo/Vehicle
Screening".
The GSN Airport/Seaport/Border Security Awards are sponsored by
Government Security News, a leading publisher of government and
homeland security news. Nominations were submitted by leading
vendors of IT and physical security products, solutions and
services used in airport, seaport, and border security,
highlighting their most noteworthy programs and projects.
"In just the last 7 months, our company has signed an Indefinite
Delivery/Indefinite Quantity contract for up to $162 million with the U.S. federal government,
received the largest QS-B220 order in our history for 1,170 units,
and has won a series of tenders in the EU, numbering in the
hundreds of units," stated Implant Sciences' CEO, Dr. Bill McGann. "Implant Sciences is actively
executing on its vision of redefining the trace detection market,
and we are very grateful that the positive attributes of our
QS-B220 have been recognized through its selection for the 'Best
Security Checkpoint' award by Government Security News."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives. With significantly lower
maintenance requirements than competing systems, the QS-B220 can be
deployed for a much lower total cost of ownership than other
approved products. Featuring a radioactive material-free design,
push-button maintenance and diagnostics, and a patented inCal™
internal automatic calibration system, the QS-B220 brings new
levels of performance and convenience to desktop trace detection
users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 60 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the 2015 GSN Airport/Seaport/Border
Security Award for "Best Security Checkpoint". All Implant
Sciences products are recognized as Qualified Anti-Terrorism
Technologies by the Department of Homeland Security. For further
details on the Company and its products, please visit the Company's
website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; and other risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-qs-b220-wins-gsn-award-for-best-security-checkpoint-300104728.html
SOURCE Implant Sciences Corporation